HBIO Q1 2026 Earnings Transcript

Harvard Bioscience reported Q1 revenue of $20.8 million, in line with guidance, with adjusted gross margin expanding 300 bps year over year to 59% and adjusted EBITDA flat at $0.8 million. NPI products rose to more than 12% of revenue from about 4% last year, and management reiterated full-year guidance for 2% to 4% revenue growth and 6% to 10% adjusted EBITDA growth. The company also highlighted improving pharma/biotech demand, a rebound in China, and progress on Project Viking, which is expected to deliver $3 million of savings in 2027 and $4 million annually thereafter.

Analysis

HBIO is starting to look less like a cyclical academic tools name and more like a three-engine story: higher-margin NPI, distribution leverage, and an operating footprint reset. The key second-order effect is that the mix shift is now doing more of the heavy lifting than top-line growth, which matters because even low-single-digit revenue growth can compound into materially better EBITDA once the company gets above a 12% NPI mix and toward the stated 60% gross margin regime.

The cleaner setup is not the quarter just reported, but the next two to three quarters. The NIH timing creates a front-loaded catalyst into Q2/Q3 as deferred academic spend converts from proposal activity into orders, while CRO demand in the Americas and Europe suggests biotech financing is already translating into real procurement rather than just pipeline chatter. If that broadens, HBIO could see a revenue inflection with less reliance on academic budgets than in prior cycles.

The main risk is that execution is being asked to do a lot of work at once: Project Viking, China localization, sales force expansion, and reinvestment in SG&A. That combination can improve the medium-term margin structure but suppress near-term earnings conversion if demand softens or if inventory normalization lags. The market may be underappreciating how much of the upside is already embedded in management’s confidence; the real surprise would be a sharper re-acceleration in Q2/Q3 rather than the guided mid-single-digit growth itself.

Key Decisions for Investors

• Long HBIO into Q2 results over the next 4-8 weeks if you can tolerate microcap volatility; use a starter position and add only on evidence that academic orders and CRO demand are converting, since the upside is driven by mix and operating leverage rather than headline growth.
• Consider a call spread on HBIO 3-6 months out to express the re-rating case with limited downside; best structure is a modestly in-the-money/near-the-money spread to capture a Q2/Q3 revenue inflection without paying for a full breakout.
• Pair trade: long HBIO / short a broader life-science tools proxy with lower mix improvement and slower margin inflection, if available in the book, to isolate the margin-compression reversal and NPI adoption story.
• If HBIO rallies hard on the print, fade into strength rather than chase; the cleaner entry is after confirmation that Q2 revenue is not just NIH timing pull-forward and that Project Viking disruptions are not diluting gross-to-EBITDA conversion.